Maze Therapeutics develops precision medicines for common diseases with large unmet medical needs, using its Compass platform and genetic insights. Its programs focus on kidney disease, including APOL1-mediated kidney disease, chronic kidney disease, and phenylketonuria.
Products & media
An oral APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease, designed from protective human genetic variants.
An oral GYS1 inhibitor licensed to Shionogi for Pompe disease, intended to reduce disease-causing glycogen production in muscle.
An oral SLC6A19 inhibitor in Phase 2 development for phenylketonuria and chronic kidney disease by reducing neutral amino-acid transport.
Team
Jobs
See all jobs for Maze Therapeutics here.
Company history
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Leads
Participating Firms
Angels